Thermo Fisher Scientific Inc. (BCBA:TMOD)
Argentina · Delayed Price · Currency is ARS · Price in USD | Market Cap | 390.50T +27.6% |
| Revenue (ttm) | 72.14T +8.3% |
| Net Income | 10.77T +7.6% |
| EPS | 1,428.36 +9.6% |
| Shares Out | n/a |
| PE Ratio | 35.98 |
| Forward PE | 25.39 |
| Dividend | 81.75 (0.16%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 23 |
| Open | 33.18 |
| Previous Close | 34.10 |
| Day's Range | 33.18 - 33.26 |
| 52-Week Range | 20.80 - 34.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 21, 2026 |
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analy... [Read more]
Financial Performance
In 2025, Thermo Fisher Scientific's revenue was $44.56 billion, an increase of 3.91% compared to the previous year's $42.88 billion. Earnings were $6.70 billion, an increase of 5.82%.
Financial numbers in USD Financial StatementsNews
Thermo Fisher price target raised to $780 from $560 at Argus
Argus analyst David Toung raised the firm’s price target on Thermo Fisher (TMO) to $780 from $560 and keeps a Buy rating on the shares. The company delivered strong Q3…
Thermo Fisher price target raised to $800 from $685 at Citi
Citi raised the firm’s price target on Thermo Fisher (TMO) to $800 from $685 and keeps a Buy rating on the shares post the Q3 report. The firm says the…
Thermo Fisher downgraded to Hold from Buy at DZ Bank
DZ Bank downgraded Thermo Fisher (TMO) to Hold from Buy with a $650 price target
Thermo Fisher price target raised to $810 from $760 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Thermo Fisher (TMO) to $810 from $760 and keeps a Buy rating on the shares. The firm said its…
Thermo Fisher price target raised to $730 from $580 at RBC Capital
RBC Capital analyst Dan Leonard raised the firm’s price target on Thermo Fisher (TMO) to $730 from $580 and keeps a Sector Perform rating on the shares. The firm cites…
Thermo Fisher price target raised to $775 from $650 at Stifel
Stifel raised the firm’s price target on Thermo Fisher (TMO) to $775 from $650 and keeps a Buy rating on the shares.
Thermo Fisher price target raised to $756 from $723 at Baird
Baird raised the firm’s price target on Thermo Fisher (TMO) to $756 from $723 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results.
Thermo Fisher price target raised to $775 from $750 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Thermo Fisher (TMO) to $775 from $750 and keeps an Overweight rating on the shares. The firm company delivered in…
Thermo Fisher raises FY26 adjusted EPS view to $25.13-$25.43 from $24.93-$25.33
Consensus $25.15. Raises FY26 revenue view to $47.7B-$48.2B from $47.4B-$48.18B, consensus $47.89B. Sees FY26 net interest expense $650M. Sees FY26 capital expenditures $1.9B-$2B. Sees FY26 free cash ...
Thermo Fisher Scientific Earnings Call Transcript: Q3 2026
Q3 revenue grew 9%, organic growth was 6%, and adjusted EPS rose 15%; stronger results prompted higher FY26 revenue, EPS, and free cash flow guidance. Growth was broad across key markets, with tariff refunds providing a one-time earnings benefit.
Thermo Fisher Scientific Earnings release: Q3 2026
Thermo Fisher Scientific released its Q3 2026 earnings on October 21, 2026, summarizing the period's financial results.
Thermo Fisher Scientific Quarterly report: Q3 2026
Thermo Fisher Scientific has published its Q3 2026 quarterly earnings report on October 21, 2026.
Thermo Fisher reports Q3 adjusted EPS $6.68, consensus $6.40
Reports Q3 revenue $12.4B, consensus $11.95B. “We are very pleased to deliver another excellent quarter, with outstanding financial performance on both the top and bottom line,” said Marc N. Casper,…
Thermo Fisher Scientific Reports Third Quarter 2026 Results
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 26, 2026. Th...
Two stocks poised to benefit from rotation out of AI
Investors looking beyond artificial intelligence (AI) should closely watch two healthcare names – Thermo Fisher Scientific (TMO) and Waters (WAT) – according to Josh Brown. In his latest report, the R...
Thermo Fisher initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Thermo Fisher (TMO) with a Buy rating and $740 price target
Thermo Fisher price target raised to $760 from $675 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Thermo Fisher (TMO) to $760 from $675 and keeps a Buy rating on the shares. The firm adjusted targets…
Thermo Fisher price target raised to $730 from $650 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Thermo Fisher (TMO) to $730 from $650 and keeps an Overweight rating on the shares.
Thermo Fisher price target raised to $745 from $650 at BofA
BofA raised the firm’s price target on Thermo Fisher (TMO) to $745 from $650 and keeps a Buy rating on the shares. The life science tools sector has further re-rated…
Thermo Fisher price target raised to $750 from $650 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Thermo Fisher (TMO) to $750 from $650 and keeps an Overweight rating on the shares. The firm adjusted targets in…
Quantum BioPharma signs contract with Thermo Fisher for sclerosis trial
Quantum BioPharma (QNTM) has entered into a Study Start-Up Agreement, or SUA, with the clinical research business of Thermo Fisher (TMO) to implement Quantum’s Phase 2 clinical trial of Lucid-21-302…
Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities to Accelerate Drug Development at CPHI Milan 2026
MILAN--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, is expanding its drug development, manufacturing, and clinical capabilities to help pharmaceutical and biotechnol...
Thermo Fisher Scientific Proteomics Technologies Enable Discovery of More Than 2,500 New Biological Associations in PRECISE-SG100K Study
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its strategic collaboration with Precision Health Research, Singapore (PRECISE...
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...